Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

95
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
95
Drug Discovery: Overview01:26

Drug Discovery: Overview

13.5K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
13.5K
Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

1.5K
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
1.5K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

11.9K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
11.9K
Synthetic Biology02:55

Synthetic Biology

5.8K
Synthetic biology is an interdisciplinary science that involves using principles from disciplines such as engineering, molecular biology, cell biology, and systems biology. It involves remodeling existing organisms from nature or constructing completely new synthetic organisms for applications such as protein or enzyme production, bioremediation, value-added macromolecule production, and the addition of desirable traits to crops, to name a few.
Golden rice
Golden rice is a genetically modified...
5.8K
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

37
Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
37

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Concizumab in patients with hemophilia A or B without inhibitors: 56-week cut-off results of the phase 3 explorer8 study.

Blood advances·2026
Same author

Cardiovascular risk scores estimate arterial thrombotic risk in aging adults with hemophilia in the ADVANCE Japan cohort.

Blood advances·2026
Same author

Monitoring of Coagulation Potential of Efanesoctocog Alfa in Haemophilia A: Insights From Conventional and Global Hemostasis Assays.

Haemophilia : the official journal of the World Federation of Hemophilia·2026
Same author

A novel humanized FIX/FX hemophilia A mouse model for preclinical evaluation of FVIIIa-mimetic bispecific antibodies.

Blood advances·2026
Same author

Repeated short-interval administration of efanesoctocog alfa is not associated with increased global coagulation potential in hemophilia A mice.

International journal of hematology·2026
Same author

Maternal-fetal transfer of emicizumab in a pregnant mouse model.

Blood advances·2026

Related Experiment Video

Updated: Apr 17, 2026

Production and Testing of Antimicrobial Peptides and Their Mimics
10:30

Production and Testing of Antimicrobial Peptides and Their Mimics

Published on: April 10, 2026

259

FVIIIa Mimetics: New Approaches and Next-Generation Initiatives.

Tadashi Matsushita1, Keiji Nogami2, Chandrakala Shanmukhaiah3

  • 1Depatment of Transfusion Medicine, Nagoya University Hospital, Nagoya, Japan.

Haemophilia : the Official Journal of the World Federation of Hemophilia
|April 16, 2026
PubMed
Summary

Next-generation therapies like Mim8 offer improved hemophilia A prophylaxis. Low-dose emicizumab may increase access but requires careful monitoring for breakthrough bleeds.

More Related Videos

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

13.2K
Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

7.4K

Related Experiment Videos

Last Updated: Apr 17, 2026

Production and Testing of Antimicrobial Peptides and Their Mimics
10:30

Production and Testing of Antimicrobial Peptides and Their Mimics

Published on: April 10, 2026

259
A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA
06:53

A Simple Alternative to Stereotactic Injection for Brain Specific Knockdown of miRNA

Published on: December 26, 2015

13.2K
Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy
12:24

Mimicking the Function of Signaling Proteins: Toward Artificial Signal Transduction Therapy

Published on: September 29, 2016

7.4K

Area of Science:

  • Hematology
  • Pharmacology
  • Global Health Equity

Background:

  • Emicizumab has advanced hemophilia A treatment, but its efficacy ceiling and global accessibility remain challenges.
  • Current treatments face limitations in achieving normal coagulation levels and equitable distribution worldwide.

Purpose of the Study:

  • To review innovations in hemophilia A therapeutics, focusing on next-generation factor VIIIa (FVIIIa) mimetics.
  • To critically assess strategies for improving global access to hemophilia A treatments, including low-dose emicizumab regimens.

Main Methods:

  • Synthesis of recent clinical trial data for novel FVIIIa mimetics, including Mim8 and NXT007.
  • Evaluation of the clinical utility and limitations of reduced-dose emicizumab in resource-limited settings.

Main Results:

  • Mim8 (denecimig) demonstrated superior prophylaxis compared to previous regimens in the FRONTIER 2 study, with flexible dosing.
  • NXT007 shows potential for achieving non-hemophilic coagulation levels in early-phase trials.
  • Low-dose emicizumab may reduce treated bleeds but carries risks of subclinical bleeding and inadequate joint health monitoring.

Conclusions:

  • Next-generation FVIIIa mimetics represent significant innovation in hemophilia A treatment, offering enhanced efficacy and dosing flexibility.
  • Low-dose emicizumab presents a potential access strategy but necessitates cautious implementation and robust monitoring to mitigate risks.
  • A balanced approach integrating therapeutic innovation with equitable access strategies is crucial for advancing global hemophilia A care.